Last reviewed · How we verify
NCT06742671: QuickDx-GCA
Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis
trial in Giant Cell Arteritis (GCA) in 100 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Groupe Hospitalier de la Rochelle Ré Aunis |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 14 February 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 March 2027 |
| Sites | 1 location across France |
Conditions studied
- Giant Cell Arteritis (GCA) — all drugs for Giant Cell Arteritis (GCA) →
Sponsor
Groupe Hospitalier de la Rochelle Ré Aunis
Who can join
50 and older, any sex, with Giant Cell Arteritis (GCA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Giant cell arteritis is a vasculitis, i.e. inflammation of the artery walls, which generally affects people over the age of 50. Diagnosis can be long and difficult, as the clinical signs are not specific (headache, pain in the jaw, scalp, shoulders and/or pelvis, abdominal pain, weight loss, etc.), but it must be made quickly, given the risk of complications. The reference method for diagnosis was initially based on clinical suspicion and analysis of a "piece of temporal artery" (biopsy) performed in the operating theatre under local anaesthetic. Since the mid-1990s, improvements in ultrasound techniques have made it possible to identify a sign, known as a halo, on the temporal arteries that is typical of patients with Giant Cell Arteritis. A prospective multicenter study published in 2024 demonstrated that, in patients with a clinical suspicion of Giant Cell Arteritis, if a halo was found on both temporal arteries by ultrasound, there was no need for a biopsy. This study is at the origin of a change in practices in the diagnosis and care of patients suffering from this disabling disease. To facilitate early diagnosis, a fast-track pathway has been set up. The aim is to make a rapid diagnosis, thereby reducing the risk of after-effects, shortening the length of hospital stays, considering outpatient treatment and limiting the number of biopsies. The investigators propose to evaluate the performance of this fast-track pathway.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06742671
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Giant Cell Arteritis (GCA)
Currently open trials in the same condition.
- NCT07246577 — The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant C · recruiting
- NCT07108387 — Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis · Phase 2 · recruiting
- NCT07001059 — oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound · NA · recruiting
- NCT06887062 — Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) · Phase 2 · recruiting
- NCT06271018 — TocILizumab in aorTitis in GCA (TILT) · recruiting
Other Groupe Hospitalier de la Rochelle Ré Aunis trials
Trials by the same sponsor.
- NCT06884397 — Use of Artificial Intelligence to Predict Complications Following Abdominal Aortic Surgery · recruiting
- NCT05418699 — Real-life Data From Diabetic Patients on Closed-loop Pumps · completed
- NCT04184375 — Cognitive Stimulation for Elderly Bipolar Patients · NA · recruiting
- NCT04310839 — Outpatient Left Laparoscopic Colectomy · completed
- NCT04610281 — The Inner Garden and Care for Children With Moderate to Severe Agitation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06742671 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier de la Rochelle Ré Aunis
- Last refreshed: 20 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06742671.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing